Evaluating the role of CDK4/6 inhibition on STAT3 activation in a transgenic mouse model of HER2-positive breast cancer

被引：0
|
作者：
Adesoye, Taiwo
Luo, Linjie
Bui, Tuyen
Kim, Serena
Wingate, Hannah
Tripathy, Debu
Hunt, Kelly
Keyomarsi, Khandan
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-25-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-25-08
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Does HER2 Affect CDK4/6 Pathway Activity in Breast Cancer?
    Cui, Xiaoyan
    Sinclair, William
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 92 - 94
  • [32] Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer
    Lee, Nathan V.
    Yuan, Jing
    Eisele, Koleen
    Cao, Joan Q.
    Painter, Cory L.
    Chionis, John
    Liu, Chaoting
    Shields, David J.
    Kan, Julie L. C.
    Arndt, Kim
    VanArsdale, Todd
    CANCER RESEARCH, 2014, 74 (19)
  • [33] NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer
    Jiang, Lili
    Ren, Liangliang
    Chen, Han
    Pan, Jinyuan
    Zhang, Zhuojun
    Kuang, Xiangqin
    Chen, Xuhong
    Bao, Wenhao
    Lin, Chun
    Zhou, Zhongqiu
    Huang, Danping
    Yang, Jianan
    Huang, Hongbiao
    Wang, Lan
    Hou, Ning
    Song, Libing
    CELL DEATH & DISEASE, 2020, 11 (07)
  • [34] NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer
    Lili Jiang
    Liangliang Ren
    Han Chen
    Jinyuan Pan
    Zhuojun Zhang
    Xiangqin Kuang
    Xuhong Chen
    Wenhao Bao
    Chun Lin
    Zhongqiu Zhou
    Danping Huang
    Jianan Yang
    Hongbiao Huang
    Lan Wang
    Ning Hou
    Libing Song
    Cell Death & Disease, 11
  • [35] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Matutino, Adriana
    Amaro, Carla
    Verma, Sunil
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [36] Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
    Migliaccio, Ilenia
    Leo, Angela
    Galardi, Francesca
    Guarducci, Cristina
    Fusco, Giulio Maria
    Benelli, Matteo
    Di Leo, Angelo
    Biganzoli, Laura
    Malorni, Luca
    CANCERS, 2021, 13 (11)
  • [37] HR-positive, HER2-negative Breast Cancer Prolongation of Survival by the CDK4 & 6 Inhibitor Abemaciclib
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) : 690 - 691
  • [38] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [39] Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2-breast cancer
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    ONCOTARGET, 2016, 7 (43) : 69111 - 69123
  • [40] Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
    Qingfei Wang
    Ian H. Guldner
    Samantha M. Golomb
    Longhua Sun
    Jack A. Harris
    Xin Lu
    Siyuan Zhang
    Nature Communications, 10
12345